The closure of a USAID global health research and development project advancing the search for an HIV vaccine affected at least 1,250 participants in ongoing trials across five countries.
Date: 3/25
Region: Global
Country: Global
Topic: Health, Research & Development
Policy Lens: Global Health Security
Entry Type: Human Impact
Additional Context: ADVANCE was a flagship PEPFAR research and development program funded by USAID to advance the search for an HIV vaccine.
When the program was terminated, there were two ongoing clinical trials. According to AVAC, the termination of this project along with other cancelled USAID global health research and development projects creates a gap in innovative, African-led HIV prevention research, and ends any PEPFAR support for HIV R&D after decades of advancement.
Devex Researcher Note: The International AIDS Vaccine Initiative, or IAVI, announced the project's closure in late February 2025, noting nearly 20 years of history. The organization also announced staff reductions at this time.
Source: AVAC